AGÕæÈ˹ٷ½

STOCK TITAN

[S-8 POS] Enstar Group SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.� On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.

  • Nature of transaction: “Aâ€� code denotes acquisition from equity award; “Fâ€� code denotes shares withheld for taxes—neither represents an open-market trade.
  • Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
  • Alignment impact: The executive retains a sizable equity stake (â‰�3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.

Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.

Panoramica della presentazione del Modulo 4: Clover Health Investments (CLOV) ha riportato attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.� Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle performance datato 16 marzo 2023. Per coprire le imposte alla fonte, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo questa vendita automatica, la proprietà diretta della Sig.ra Reynoso è di 3.328.328 azioni di Classe A, in aumento di circa 132 mila azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “Aâ€� indica acquisizione tramite premio azionario; il codice “Fâ€� indica azioni trattenute per tasse—nessuno dei due rappresenta una compravendita sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in denaro per l’insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull’allineamento: L’amministratore mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in denaro.

In generale, la presentazione riflette una normale maturazione di compensi azionari e la relativa ritenuta fiscale, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale, salvo altri fattori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, identificada como “CEO, Medicare Advantage.� El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a $2.79 por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132 mil acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “Aâ€� indica adquisición por premio de acciones; el código “Fâ€� indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación accionaria significativa (â‰�3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó nueva inversión en efectivo.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la retención fiscal relacionada, en lugar de una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)ëŠ� “Medicare Advantage CEOâ€ë¡œ 등재ë� Jamie L. Reynosoì� ë‚´ë¶€ìž� 활ë™ì� 보고했습니다. 2025ë…� 6ì›� 30ì�, Reynoso 씨는 2023ë…� 3ì›� 16ì� 성과 기반 RSU 수여ì� 마지ë§� ë¶„í• ë¡� 217,523ì£� í´ëž˜ìŠ� A 주ì‹ì� ì·¨ë“했습니다. ì›ì²œì§•수 세금ì� 충당하기 위해 회사ëŠ� ìžë™ìœ¼ë¡œ 85,596주를 주당 2.79달러ì—� 매ë„했습니다. ìžë™ ë§¤ë„ í›� Reynoso ì”¨ì˜ ì§ì ‘ 소유 주ì‹ì€ 3,328,328ì£� í´ëž˜ìŠ� Aë¡�, ì´ì „ 잔고보다 ì•� 13ë§� 2ì²� ì£� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

  • 거래 성격: “Aâ€� 코드ëŠ� ì£¼ì‹ ìˆ˜ì—¬ì—� 따른 ì·¨ë“ì�, “Fâ€� 코드ëŠ� 세금 ì›ì²œì§•수ë¥� 위한 ì£¼ì‹ ë³´ìœ ë¥� ì˜ë¯¸í•˜ë©°, ë‘� ë‹� 공개 시장 거래ëŠ� 아닙니다.
  • ì›ê°€ 기준: RSUëŠ� ë‚´ë¶€ìžì—ê²� 현금 비용 ì—†ì´ ì •ì‚°ë˜ì—ˆìœ¼ë©°, 세금 ì›ì²œì§•수ë¥� 위한 매ë„ë§� 시장 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�.
  • ì •ë ¬ ì˜í–¥: ìž„ì›ì€ ìƒë‹¹í•� ì§€ë¶�(ì•� 330ë§� ì£�)ì� 유지하여 ì¸ì„¼í‹°ë¸Œ ì •ë ¬ì� 강화하지ë§�, 새로ìš� 현금 투ìžëŠ� ì´ë£¨ì–´ì§€ì§€ 않았습니ë‹�.

ì „ë°˜ì ìœ¼ë¡� ì´ë²ˆ ì œì¶œì€ ìž„ì˜ì� 매매 결정보다ëŠ� 정기ì ì¸ ì£¼ì‹ ë³´ìƒ ì„±ìˆ™ ë°� ê´€ë � 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�. 다른 촉매가 없는 í•� 시장 ì˜í–¥ì€ 중립ì �ì� 것으ë¡� 예ìƒë©ë‹ˆë‹�.

Présentation générale du formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, indiquée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de Classe A via la dernière tranche d’une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les impôts à la source, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de Classe A, soit une augmentation d’environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition via attribution d’actions ; le code « F » désigne des actions retenues pour impôts â€� aucune des deux n’est une transaction sur le marché libre.
  • Base de coût : Les RSU ont été attribuées sans coût en numéraire pour l’initié ; seule la vente pour retenue fiscale est au prix du marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en numéraire n’a été réalisé.

Dans l’ensemble, le dépôt reflète une acquisition régulière de rémunération en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre en l’absence d’autres catalyseurs.

Überblick zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insider-Aktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.� Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien aus der letzten Tranche einer leistungsbasierten RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was etwa 132.000 Aktien mehr sind als zuvor.

  • Art der Transaktion: Der Code „Aâ€� steht für Erwerb durch Aktienzuteilung; „Fâ€� steht für einbehaltene Aktien zur Steuerzahlung â€� beides keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Barausgabe an den Insider ausgegeben; nur der Verkauf zur Steuerabführung hat einen Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft hält eine beträchtliche Aktienbeteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Bareinlage getätigt.

Insgesamt spiegelt die Einreichung eine routinemäßige Aktienvergütung und zugehörige Steuerabführung wider, keine freiwillige Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser eintreten.

Positive
  • Executive ownership rises by ~132,000 shares, increasing alignment with shareholders.
  • Performance-based vesting suggests the company met or exceeded predefined targets tied to the 2023 RSU grant.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting—neutral impact; insider’s stake increases, no open-market buying.

The 217.5 k share addition arises from a scheduled performance-based RSU vesting. The automatic 85.6 k-share sale merely covers payroll taxes. Net beneficial ownership growth of ~132 k shares (�4 % of her prior holdings) is not large enough to signal a strong incremental vote of confidence, but it modestly enhances alignment. Because there is no discretionary purchase or sale, I view the filing as informational, not directional. Trading volume impact should be minimal.

TL;DR: Performance-based vesting confirms compensation plan progression; governance concerns minimal.

The disclosure shows Clover Health’s incentive structure functioning as designed: shares vest only after performance hurdles, with automatic tax withholding to avoid insider liquidity strain. The executive’s continued sizable ownership (3.3 M shares) exceeds common ownership guidelines, fostering shareholder alignment. There are no indications of problematic timing, 10b5-1 usage, or unusual dispositions. Therefore, the governance signal is neutral-to-slightly-positive, but not materially impactful to valuation.

Panoramica della presentazione del Modulo 4: Clover Health Investments (CLOV) ha riportato attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.� Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle performance datato 16 marzo 2023. Per coprire le imposte alla fonte, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo questa vendita automatica, la proprietà diretta della Sig.ra Reynoso è di 3.328.328 azioni di Classe A, in aumento di circa 132 mila azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “Aâ€� indica acquisizione tramite premio azionario; il codice “Fâ€� indica azioni trattenute per tasse—nessuno dei due rappresenta una compravendita sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in denaro per l’insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull’allineamento: L’amministratore mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in denaro.

In generale, la presentazione riflette una normale maturazione di compensi azionari e la relativa ritenuta fiscale, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale, salvo altri fattori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, identificada como “CEO, Medicare Advantage.� El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a $2.79 por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132 mil acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “Aâ€� indica adquisición por premio de acciones; el código “Fâ€� indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación accionaria significativa (â‰�3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó nueva inversión en efectivo.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la retención fiscal relacionada, en lugar de una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)ëŠ� “Medicare Advantage CEOâ€ë¡œ 등재ë� Jamie L. Reynosoì� ë‚´ë¶€ìž� 활ë™ì� 보고했습니다. 2025ë…� 6ì›� 30ì�, Reynoso 씨는 2023ë…� 3ì›� 16ì� 성과 기반 RSU 수여ì� 마지ë§� ë¶„í• ë¡� 217,523ì£� í´ëž˜ìŠ� A 주ì‹ì� ì·¨ë“했습니다. ì›ì²œì§•수 세금ì� 충당하기 위해 회사ëŠ� ìžë™ìœ¼ë¡œ 85,596주를 주당 2.79달러ì—� 매ë„했습니다. ìžë™ ë§¤ë„ í›� Reynoso ì”¨ì˜ ì§ì ‘ 소유 주ì‹ì€ 3,328,328ì£� í´ëž˜ìŠ� Aë¡�, ì´ì „ 잔고보다 ì•� 13ë§� 2ì²� ì£� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

  • 거래 성격: “Aâ€� 코드ëŠ� ì£¼ì‹ ìˆ˜ì—¬ì—� 따른 ì·¨ë“ì�, “Fâ€� 코드ëŠ� 세금 ì›ì²œì§•수ë¥� 위한 ì£¼ì‹ ë³´ìœ ë¥� ì˜ë¯¸í•˜ë©°, ë‘� ë‹� 공개 시장 거래ëŠ� 아닙니다.
  • ì›ê°€ 기준: RSUëŠ� ë‚´ë¶€ìžì—ê²� 현금 비용 ì—†ì´ ì •ì‚°ë˜ì—ˆìœ¼ë©°, 세금 ì›ì²œì§•수ë¥� 위한 매ë„ë§� 시장 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�.
  • ì •ë ¬ ì˜í–¥: ìž„ì›ì€ ìƒë‹¹í•� ì§€ë¶�(ì•� 330ë§� ì£�)ì� 유지하여 ì¸ì„¼í‹°ë¸Œ ì •ë ¬ì� 강화하지ë§�, 새로ìš� 현금 투ìžëŠ� ì´ë£¨ì–´ì§€ì§€ 않았습니ë‹�.

ì „ë°˜ì ìœ¼ë¡� ì´ë²ˆ ì œì¶œì€ ìž„ì˜ì� 매매 결정보다ëŠ� 정기ì ì¸ ì£¼ì‹ ë³´ìƒ ì„±ìˆ™ ë°� ê´€ë � 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�. 다른 촉매가 없는 í•� 시장 ì˜í–¥ì€ 중립ì �ì� 것으ë¡� 예ìƒë©ë‹ˆë‹�.

Présentation générale du formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, indiquée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de Classe A via la dernière tranche d’une attribution de RSU basée sur la performance du 16 mars 2023. Pour couvrir les impôts à la source, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de Classe A, soit une augmentation d’environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition via attribution d’actions ; le code « F » désigne des actions retenues pour impôts â€� aucune des deux n’est une transaction sur le marché libre.
  • Base de coût : Les RSU ont été attribuées sans coût en numéraire pour l’initié ; seule la vente pour retenue fiscale est au prix du marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en numéraire n’a été réalisé.

Dans l’ensemble, le dépôt reflète une acquisition régulière de rémunération en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre en l’absence d’autres catalyseurs.

Überblick zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insider-Aktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.� Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien aus der letzten Tranche einer leistungsbasierten RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was etwa 132.000 Aktien mehr sind als zuvor.

  • Art der Transaktion: Der Code „Aâ€� steht für Erwerb durch Aktienzuteilung; „Fâ€� steht für einbehaltene Aktien zur Steuerzahlung â€� beides keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Barausgabe an den Insider ausgegeben; nur der Verkauf zur Steuerabführung hat einen Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft hält eine beträchtliche Aktienbeteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Bareinlage getätigt.

Insgesamt spiegelt die Einreichung eine routinemäßige Aktienvergütung und zugehörige Steuerabführung wider, keine freiwillige Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser eintreten.

 

As filed with the Securities and Exchange Commission on July 2, 2025

 

Registration Statement No. 333-141793

Registration Statement No. 333-148862

Registration Statement No. 333-148863

Registration Statement No. 333-149551

Registration Statement No. 333-212131

Registration Statement No. 333-237259

Registration Statement No. 333-265567

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-141793

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-148862

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-148863

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-149551

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-212131

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237259

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-265567

 

 

UNDER

THE SECURITIES ACT OF 1933

 

  

ENSTAR GROUP LIMITED

(Exact name of registrant as specified in its charter)

 

   

Bermuda   N/A

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

A.S. Cooper Building, 4th Floor, 26 Reid Street

Hamilton HM 11, Bermuda

(Address of Principal Executive Offices)

 

  

Enstar Group Limited 2006 Equity Incentive Plan
(formerly the Castlewood Holdings Limited 2006 Equity Incentive Plan)

The Enstar Group, Inc. 1997 Omnibus Incentive Plan
The Enstar Group, Inc. 2001 Outside Directors Stock Option Plan

Enstar Group Limited Deferred Compensation and Ordinary Share Plan for Non-Employee Directors

Enstar Group Limited Employee Share Purchase Plan

Enstar Group Limited 2016 Equity Incentive Plan

Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan

(Full title of the plans)

 

  

Enstar (US) Inc.

55 West 46th Street, Suite 2805

New York, NY 10036

(212) 790-9700

(Name, address and telephone number, including area code, of agent for service)

 

Copies of all communications, including communications sent to agent for service, should be sent to:

 

Katherine M. Krause

Xiaohui (Hui) Lin

Louis H. Argentieri

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, New York 10017

(212) 455-2000

Enstar Group Limited

A.S. Cooper Building, 4th Floor, 26 Reid Street

Hamilton HM 11, Bermuda

(441) 292-3645

 

  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer x   Accelerated filer ¨
       
Non-accelerated filer ¨   Smaller reporting company ¨
       
      Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

EXPLANATORY NOTE

 

Enstar Global Limited, an exempted company limited by shares existing under the laws of Bermuda (the “Company”, “Enstar”, or the “Registrant”), is filing with the Securities and Exchange Commission (the “Commission”) these post-effective amendments (these “Post-Effective Amendments”) to deregister any and all securities previously registered under the following Registration Statements on Form S-8 (the “Registration Statements”) that remain unsold or otherwise unissued under each such Registration Statement as of the date hereof (note that the share numbers listed below do not take into account corporate actions taken in the interim):

 

·Registration Statement No. 333-141793 filed with the Commission on April 2, 2007, registering 1,200,000 ordinary shares issuable pursuant to the Enstar Group Limited 2006 Equity Incentive Plan;
·Registration Statement No. 333-148862 filed with the Commission on January 25, 2008, registering 460,949 ordinary shares issuable pursuant to The Enstar Group, Inc. 1997 Omnibus Incentive Plan and 29,422 ordinary shares issuable pursuant to The Enstar Group, Inc. 2001 Outside Director’s Stock Option Plan;
·Registration Statement No. 333-148863 filed with the Commission on January 25, 2008, registering 97,862 ordinary shares issuable pursuant to the Enstar Group Limited Deferred Compensation Plan for Non-Employee Directors;
·Registration Statement No. 333-149551 filed with the Commission on March 5, 2008, registering 200,000 ordinary shares issuable pursuant to the Enstar Group Limited Employee Share Purchase Plan;
·Registration Statement No. 333-212131 filed with the Commission on June 20, 2016, registering 689,654 ordinary shares issuable pursuant to the Enstar Group Limited 2016 Equity Incentive Plan;
·Registration Statement No. 333-237259 filed with the Commission on March 18, 2020, registering 84,370 ordinary shares issuable pursuant to the Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan;
·Registration Statement No. 333-265567 filed with the Commission on June 14, 2022, registering 400,000 ordinary shares issuable pursuant to the Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan.

 

On July 2, 2025, pursuant to the Agreement and Plan of Merger dated as of July 29, 2024, by and among Enstar, Elk Bidco Limited, an exempted company limited by shares existing under the laws of Bermuda (“Parent”), Elk Merger Sub Limited, an exempted company limited by shares existing under the laws of Bermuda and a directly wholly owned subsidiary of Parent, Deer Ltd., an exempted company limited by shares existing under the laws of Bermuda and a direct wholly owned subsidiary of the Company, and Deer Merger Sub Ltd., an exempted company limited by shares existing under the laws of Bermuda and a direct wholly owned subsidiary of Deer Ltd., the parties effected a series of mergers (collectively, the “Mergers”), with Enstar surviving the Mergers as a wholly owned subsidiary of Parent. These Post-Effective Amendments are being filed as a result of the Mergers.

 

The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements as of the date hereof. These filings are made in accordance with an undertaking made by the Company in Part II of each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance but remain unsold at the termination of the offering.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Hamilton, Bermuda on July 2, 2025.

 

  ENSTAR GROUP LIMITED
   
  By: /s/ Audrey B. Taranto
  Name: Audrey B. Taranto
  Title: General Counsel

 

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

 

 

 

FAQ

What insider transaction did Jamie L. Reynoso report for CLOV?

217,523 RSUs vested and 85,596 shares were withheld for taxes on 30 June 2025.

How many Clover Health shares does Reynoso own after the Form 4 filing?

She now directly owns 3,328,328 Class A shares.

Were any open-market purchases or sales involved?

No. The acquisition came from RSU vesting; the share sale was automatic tax withholding, not discretionary trading.

At what price were shares sold to cover taxes?

Shares were sold at $2.79 per share.

Does the filing indicate use of a Rule 10b5-1 plan?

No Rule 10b5-1 box is marked; the sale was automatic for tax withholding.
Enstar Group Limited

NASDAQ:ESGR

ESGR Rankings

ESGR Latest News

ESGR Latest SEC Filings

ESGR Stock Data

5.01B
11.78M
10.79%
84.93%
1.11%
Insurance - Diversified
Fire, Marine & Casualty Insurance
Bermuda
HAMILTON